News & Updates

Among patients with ulcerative colitis (UC), treatment with biologic agents may lead to longer remission durations, a recent study has found. However, biologics appear to have no effect on the risk of resection, particularly in moderate to severe active disease.

In individuals with Wilson disease (WD), a rare disease of copper metabolism, ALXN1840 led to significantly greater copper mobilization compared with standard of care (SoC), findings from a rater-blinded phase III study have shown.

Treatment with maralixibat significantly reduced the severity of pruritus in children with progressive familial intrahepatic cholestasis (PFIC) in the MARCH-PFIC* study presented at The Liver Meeting 2022.

Treatment with odevixibat, a potent, selective IBAT* inhibitor, significantly improved pruritus and reduced serum bile acid levels in children with Alagille syndrome (ALGS), according to the ASSERT** trial presented at The Liver Meeting 2022.